IZERVAY (Avacincaptad Pegol Sodium) Patent Expiration, LOE Window & CMS Spending
IZERVAY (Avacincaptad Pegol Sodium) by Astellas Pharma: FDA Orange Book core substance LOE 2027-02-14 (last listed 2034-07-11), 0 AB generics, $0 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Astellas Pharma |
| FDA Application & Pathway | N217225 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2027-02-14 |
| Last Listed Patent or Exclusivity Date | 2034-07-11 |
| Orange Book Patents (*PED Extensions) | 6 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.